JJ'Studio - Fotolia
BOSTON -- With the FDA indicating its mobile health (mHealth) app regulation will be mostly hands-off, with a small minority of apps subject to clinical trials and premarket approval, who can healthcare provider CIOs trust to provide safe apps for their patients and care workflows?
Joseph Cafazzo, lead for the University of Toronto's Centre for Global eHealth Innovation, offered the perspective of both an app developer and healthcare provider who has worked for Bant, a teenage diabetes management app, and worked on clinical trials measuring its safety and efficacy. We spoke with him at the mHealth and Telehealth World 2014 conference.
Cafazzo and his organization, of course, want to eventually bring the mHealth app to market in the United States. He has a unique perspective on the value of clinical trials for apps, which take years to conduct and publish the findings. He offered his take on how apps should and shouldn't be regulated, and provided CIOs with a few pointers on choosing patient apps for their organizations in what is a mostly unregulated market.
List of top 10 most popular mHealth apps shows users value mobile security
Will the popularity of mHealth apps pave the way for a healthcare-specific virtual assistant?
Mobile devices, applications diversify remote treatment options